Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))

G. N. Hortobagyi, S. M. Stemmer, H. A. Burris, Y. S. Yap, G. S. Sonke, S. Paluch-Shimon, M. Campone, K. Petrakova, K. L. Blackwell, E. P. Winer, W. Janni, S. Verma, P. Conte, C. L. Arteaga, D. A. Cameron, S. Mondal, F. Su, M. Miller, M. Elmeliegy, C. GermaJ. O'Shaughnessy

Research output: Contribution to journalComment/debate

Abstract

Ann Oncol 2018; 29: 1541–1547 (doi: 10.1093/annonc/mdy155) The following has been added to the ‘Disclosure’ section: “CLA reports fees for advisory work with Novartis Pharmaceuticals (specifically participation on a Steering Committee for a clinical trial).”

Original languageEnglish (US)
Number of pages1
JournalAnnals of Oncology
Volume30
Issue number11
DOIs
StatePublished - Nov 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155))'. Together they form a unique fingerprint.

  • Cite this

    Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y. S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K. L., Winer, E. P., Janni, W., Verma, S., Conte, P., Arteaga, C. L., Cameron, D. A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., ... O'Shaughnessy, J. (2019). Erratum: Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer (Annals of Oncology (2018) 29(7) (1541–1547), (S0923753419321052), (10.1093/annonc/mdy155)). Annals of Oncology, 30(11). https://doi.org/10.1093/annonc/mdz215